PTC Therapeutics (PTCT) CTO awarded 17,500 RSUs and 43,750-share option

Rhea-AI Filing Summary

PTC Therapeutics chief technical operations officer Neil Gregory Almstead received new equity awards in the company. On January 2, 2026 he was granted 17,500 restricted stock units that vest in four equal annual installments starting January 2, 2027. He also indirectly holds 6,956 shares of common stock through his spouse, including 520 shares from this grant and 257 shares acquired under the employee stock purchase plan for the period ended December 31, 2025.

In addition, he received a stock option for 43,750 shares of common stock at an exercise price of $76.74 per share. This option was granted on January 2, 2026 and vests over four years, with 25% vesting on January 2, 2027 and a further 6.25% of the original shares vesting at the end of each successive three‑month period beginning April 2, 2027. After these transactions he beneficially owns 118,382 shares directly and the 6,956 shares indirectly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Almstead Neil Gregory

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNICAL OPS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		17,500(1)	A	$0	118,382(2)	D
Common Stock	01/02/2026		A		520(1)	A	$0	6,956(2)	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$76.74	01/02/2026		A		43,750		(3)	01/01/2036	Common Stock	43,750	$0	43,750	D

Explanation of Responses:

1. Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.

2. Includes 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025.

3. This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.

	/s/ Avraham S. Adler, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did PTC Therapeutics (PTCT) grant to Neil Gregory Almstead?

On January 2, 2026, Neil Gregory Almstead received 17,500 restricted stock units of PTC Therapeutics common stock and a stock option for 43,750 shares with an exercise price of $76.74 per share.

How do the new restricted stock units for PTCT's CTO vest?

The 17,500 restricted stock units granted on January 2, 2026 vest in four equal installments over four years, starting on January 2, 2027.

What is the vesting schedule of the new stock option granted to the PTC Therapeutics officer?

The 43,750-share stock option granted on January 2, 2026 vests over four years: 25% vests on January 2, 2027, and an additional 6.25% of the original shares vests at the end of each three-month period starting April 2, 2027, until fully vested by its January 1, 2036 expiration.

How many PTC Therapeutics shares does Neil Gregory Almstead own after these transactions?

Following the reported grants, Neil Gregory Almstead beneficially owns 118,382 shares of PTC Therapeutics common stock directly and 6,956 shares indirectly through his spouse.

What indirect PTC Therapeutics share ownership is reported for the officer and how was it acquired?

Almstead indirectly owns 6,956 shares of PTC Therapeutics common stock by spouse, which includes 520 shares from the January 2, 2026 grant and 257 shares acquired under the employee stock purchase plan for the period ended December 31, 2025.

Did the PTC Therapeutics officer pay for the new stock and option grants?

The Form 4 shows the 17,500 restricted stock units, the 520 indirect shares, and the 43,750-share stock option were all reported at a price of $0, indicating they were granted as compensation rather than purchased in the market.